Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

SNDXSyndax Pharmaceuticals Inc

Nasdaq · CIK 0001395937
Filer categoryLarge accelerated filer
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts325

Identity from submissions API

NameSyndax Pharmaceuticals Inc
CIK0001395937
TickersSNDX
ExchangesNasdaq
Entity typeoperating
CategoryLarge accelerated filer
SIC2834 Pharmaceutical Preparations
EIN320162505
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone781-419-1400
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
730 THIRD AVENUE
9TH FLOOR
NEW YORK
NY
10017
NY
Mailing address
730 THIRD AVENUE
9TH FLOOR
NEW YORK
NY
10017
NY

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

660 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-12 4 4 0001193125-26-458304 5630
2026-11-12 3 3 0001193125-26-458245 3056
2026-11-10 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000728 005-89449 261538359 34 8129
2026-11-02 10-Q 10-Q 0001193125-26-443625 001-37708 261512258 34 9229987 1 1
2026-11-02 8-K 8-K 2.02,5.02,9.01 0001193125-26-443613 001-37708 261512219 34 7727732 1 1
2026-10-30 4 4 0001193125-26-442119 8643
2026-10-29 144 xsl144X01/primary_doc.xml 0001950047-26-010480 001-37708 261502147 33 4783
2026-08-07 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000093751-26-000542 005-89449 261252336 34 8255
2026-08-04 10-Q 10-Q 0001193125-26-332750 001-37708 261238463 34 9127423 1 1
2026-08-04 8-K 8-K 2.02,9.01 0001193125-26-332736 001-37708 261238399 34 8615371 1 1
2026-07-14 8-K 8-K 8.01,9.01 0001193125-26-302608 001-37708 261172588 34 37205865 1 1
2026-07-09 4 4 0001193125-26-299803 8642
2026-07-08 144 xsl144X01/primary_doc.xml 0001950047-26-006967 001-37708 261162786 33 5552
2026-06-12 4 4 0001193125-26-269694 13881
2026-06-12 144 xsl144X01/primary_doc.xml 0001959173-26-004618 001-37708 261086744 33 5085
2026-06-11 144 xsl144X01/primary_doc.xml 0001959173-26-004566 001-37708 261083156 33 5518
2026-06-10 8-K 8-K 1.01,2.03,3.02,9.01 0001193125-26-266027 001-37708 261080530 34 1060964 1 1
2026-06-10 8-K 8-K 5.02,5.07,9.01 0001193125-26-265852 001-37708 261079830 34 769347 1 1
2026-06-04 DEFA14A DEFA14A 0001193125-26-256557 001-37708 261063311 34 276830 1 1
2026-06-04 8-K 8-K 1.01,2.03,3.02,8.01,9.01 0001193125-26-256458 001-37708 261063204 34 303236 1 1
2026-06-02 4 4 0001193125-26-253603 4783
2026-06-02 4 4 0001193125-26-253601 4818
2026-06-01 144 xsl144X01/primary_doc.xml 0001959173-26-004218 001-37708 261050340 33 4479
2026-06-01 144 xsl144X01/primary_doc.xml 0001959173-26-004216 001-37708 261050284 33 4559
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-003472 005-89449 26987911 34 12282
2026-04-30 ARS ARS 0001193125-26-197892 001-37708 26927365 34 2422293
2026-04-30 DEFA14A DEFA14A 0001193125-26-197877 001-37708 26927332 34 1565586 1 1
2026-04-30 DEF 14A DEF 14A 0001193125-26-197859 001-37708 26927293 34 7306385 1 1
2026-04-30 10-Q 10-Q 0001193125-26-197154 001-37708 26924975 34 7068258 1 1
2026-04-30 8-K 8-K 2.02,9.01 0001193125-26-197124 001-37708 26924864 34 9840735 1 1
2026-04-30 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002100119-26-001081 005-89449 26922961 34 7417
2026-03-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-002306 005-89449 26804556 34 7182
2026-02-26 S-8 S-8 0001193125-26-076822 333-293792 26689041 33 303806 1 1
2026-02-26 10-K 10-K 0001193125-26-076536 001-37708 26687785 34 16365412 1 1
2026-02-26 8-K 8-K 2.02,9.01 0001193125-26-076522 001-37708 26687661 34 8529824 1 1
2026-02-10 4 4 0001193125-26-043814 4681
2026-02-10 4 4 0001193125-26-043813 4645
2026-02-09 144 xsl144X01/primary_doc.xml 0001959173-26-000773 001-37708 26611344 33 5211
2026-02-09 144 xsl144X01/primary_doc.xml 0001959173-26-000771 001-37708 26611269 33 5101
2026-02-09 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000093751-26-000090 005-89449 26609679 34 8050
2026-02-06 4 4 0001193125-26-041500 10657
2026-02-06 4 4 0001193125-26-041497 12251
2026-02-06 4 4 0001193125-26-041412 4757
2026-02-06 4 4 0001193125-26-041344 4759
2026-02-06 4 4 0001193125-26-041334 9035
2026-02-06 4 4 0001193125-26-041200 4819
2026-02-06 4 4 0001193125-26-041194 4748
2026-02-06 4 4 0001193125-26-041192 4763
2026-02-06 4 4 0001193125-26-041167 4741
2026-02-06 144 xsl144X01/primary_doc.xml 0001959173-26-000725 001-37708 26607410 33 4561
2026-02-06 144 xsl144X01/primary_doc.xml 0001959173-26-000723 001-37708 26607388 33 4470
2026-01-30 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000102909-26-000252 005-89449 26582583 34 7019
2026-01-12 8-K 8-K 2.02,7.01 0001193125-26-010486 001-37708 26527232 34 225500 1 1
2025-12-19 8-K 8-K 5.03 0001193125-25-326961 001-37708 251587955 34 440576 1 1
2025-12-01 4 4 0001193125-25-303941 4360
2025-11-03 10-Q 10-Q 0001193125-25-262521 001-37708 251444023 34 7984576 1 1
2025-11-03 8-K 8-K 2.02,9.01 0001193125-25-262509 001-37708 251443976 34 8850334 1 1
2025-10-24 8-K 8-K 8.01,9.01 0001193125-25-250052 001-37708 251416638 34 248443 1 1
2025-09-08 4 4 0000950170-25-113659 8593
2025-09-08 144 xsl144X01/primary_doc.xml 0001950047-25-006849 001-37708 251300327 33 5553
2025-08-18 4 4 0000950170-25-109815 20336
2025-08-18 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003741 005-89449 251228534 34 16537
2025-08-18 144 xsl144X01/primary_doc.xml 0001950047-25-005995 001-37708 251228393 33 6230
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003706 005-89449 251221359 34 12146
2025-08-14 144 xsl144X01/primary_doc.xml 0001950047-25-005839 001-37708 251219759 33 5019
2025-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000769993-25-000479 005-89449 251213282 34 16885
2025-08-07 4 4 0000950170-25-105258 4662
2025-08-04 10-Q 10-Q 0000950170-25-101985 001-37708 251180240 34 8381561 1 1
2025-08-04 8-K 8-K 2.02,9.01 0000950170-25-101974 001-37708 251180127 34 7546354 1 1
2025-07-18 4 4 0000950170-25-096948 4633
2025-07-18 4 4 0000950170-25-096947 4669
2025-07-16 144 xsl144X01/primary_doc.xml 0001959173-25-004606 001-37708 251127270 33 4467
2025-07-16 144 xsl144X01/primary_doc.xml 0001959173-25-004605 001-37708 251127243 33 4554
2025-07-10 144 xsl144X01/primary_doc.xml 0001959173-25-004535 001-37708 251116197 33 4467
2025-06-26 8-K 8-K 5.02 0000950170-25-090205 001-37708 251075229 34 145209 1 1
2025-05-19 4 4 0000950170-25-074304 4487
2025-05-19 4 4 0000950170-25-074301 4394
2025-05-19 4 4 0000950170-25-074297 4353
2025-05-19 4 4 0000950170-25-074289 4354
2025-05-16 3 3 0000950170-25-073559 5660
2025-05-16 8-K 8-K 5.02,7.01,9.01 0000950170-25-073555 001-37708 25959426 34 517609 1 1
2025-05-09 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000769993-25-000250 005-89449 25929272 34 16570
2025-05-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000895421-25-000369 005-89449 25920044 34 12220
2025-05-05 10-Q 10-Q 0000950170-25-063518 001-37708 25912832 34 7409594 1 1
2025-05-05 8-K 8-K 2.02,8.01,9.01 0000950170-25-063514 001-37708 25912781 34 407293 1 1
2025-04-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001576419-25-000656 005-89449 25844563 34 11009
2025-04-01 ARS ARS 0000950170-25-048489 001-37708 25799582 34 1840932
2025-04-01 DEFA14A DEFA14A 0000950170-25-048476 001-37708 25799546 34 866060
2025-04-01 DEF 14A DEF 14A 0000950170-25-048472 001-37708 25799512 34 11570907 1 1
2025-03-17 4 4 0000950170-25-039787 6556
2025-03-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902219-25-000138 005-89449 25718294 34 15354
2025-03-06 4 4 0000950170-25-034634 8586
2025-03-04 144 xsl144X01/primary_doc.xml 0001950047-25-001520 001-37708 25706196 33 4787
2025-03-04 S-8 S-8 0000950170-25-031354 333-285529 25701793 33 590154 1 1
2025-03-03 10-K 10-K 0000950170-25-030394 001-37708 25693737 34 14912014 1 1
2025-03-03 8-K 8-K 2.02,8.01,9.01 0000950170-25-030392 001-37708 25693734 34 446172 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001085146-25-001726 005-89449 25630974 34 9428
2025-02-12 4 4 0000950170-25-019005 4666
2025-02-12 4 4 0000950170-25-019000 4703
2025-02-12 4 4 0000950170-25-018993 4672
2025-02-12 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000769993-25-000129 005-89449 25613343 34 16479
2025-02-10 144 xsl144X01/primary_doc.xml 0001959173-25-000841 001-37708 25605461 33 4518
2025-02-10 144 xsl144X01/primary_doc.xml 0001959173-25-000835 001-37708 25605436 33 4603
2025-02-10 144 xsl144X01/primary_doc.xml 0001959173-25-000833 001-37708 25605424 33 4509
2025-02-07 4 4 0000950170-25-016391 9054
2025-02-07 4 4 0000950170-25-016389 9051
2025-02-07 4 4 0000950170-25-016384 9106
2025-02-07 4 4 0000950170-25-016380 4805
2025-02-07 4 4 0000950170-25-016374 4760
2025-02-07 4 4 0000950170-25-016369 4788
2025-02-07 4 4 0000950170-25-016363 4798
2025-02-07 4 4 0000950170-25-016357 4800
2025-02-07 4 4 0000950170-25-016351 4800
2025-02-07 4 4 0000950170-25-016346 4781
2025-02-05 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000895421-25-000232 005-89449 25591242 34 11829
2025-01-22 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-000388 005-89449 25547046 34 16985
2024-12-20 8-K 8-K 5.02 0000950170-24-139121 001-37708 241568736 34 153267 1 1
2024-12-06 SC 13G/A us87164f1057_120624.txt 0002012383-24-004541 005-89449 241532639 34 14017
2024-11-18 8-K 8-K 8.01,9.01 0000950170-24-127708 001-37708 241469272 34 236698 1 1
2024-11-12 8-K 8-K 8.01,9.01 0000950170-24-124545 001-37708 241443215 34 225476 1 1
2024-11-08 SC 13G/A us87164f1057_110824.txt 0002012383-24-004032 005-89449 241442076 34 13987
2024-11-08 SC 13G/A SEC SCHEDULE 13G 0000902219-24-000479 005-89449 241438643 34 36192
2024-11-05 10-Q 10-Q 0000950170-24-121439 001-37708 241427376 34 8229746 1 1
2024-11-05 8-K 8-K 2.02,9.01 0000950170-24-121437 001-37708 241427350 34 385247 1 1
2024-11-04 8-K 8-K 1.01 0000950170-24-120673 001-37708 241423436 34 158398 1 1
2024-10-21 SC 13G/A us87164f1057_102124.txt 0002012383-24-000892 005-89449 241383520 34 13975
2024-10-18 SC 13G/A Syndax_Pharmaceuticals_Inc.htm 0000093751-24-000879 005-89449 241379444 34 56042
2024-08-01 10-Q 10-Q 0000950170-24-089241 001-37708 241166495 34 7535746 1 1
2024-08-01 8-K 8-K 2.02,9.01 0000950170-24-089235 001-37708 241166446 34 372318 1 1
2024-06-17 4 PRIMARY DOCUMENT 0001562180-24-005118 4742
2024-05-16 4 PRIMARY DOCUMENT 0001562180-24-004087 5510
2024-05-16 3 PRIMARY DOCUMENT 0001562180-24-004086 3185
2024-05-15 8-K 8-K 5.02,5.07,7.01,9.01 0000950170-24-060462 001-37708 24950775 34 217271 1 1
2024-05-08 10-Q 10-Q 0000950170-24-055053 001-37708 24924199 34 6388749 1 1
2024-05-08 8-K 8-K 2.02,9.01 0000950170-24-055052 001-37708 24924191 34 341359 1 1
2024-04-02 ARS ARS 0000950170-24-040230 001-37708 24814732 34 2073349
2024-04-02 DEFA14A DEFA14A 0000950170-24-040128 001-37708 24814078 34 2056470
2024-04-02 DEF 14A DEF 14A 0000950170-24-040099 001-37708 24814027 34 6496430 1 1
2024-03-18 8-K 8-K 5.02,7.01,9.01 0000950170-24-032514 001-37708 24756901 34 469336 1 1
2024-02-27 S-3ASR S-3ASR 0001193125-24-048135 333-277424 24688741 33 2234526
2024-02-27 S-8 S-8 0001193125-24-048118 333-277423 24688619 33 86596
2024-02-27 10-K 10-K 0000950170-24-021253 001-37708 24687479 34 12877333 1 1
2024-02-27 8-K 8-K 2.02,9.01 0000950170-24-021086 001-37708 24686379 34 359799 1 1
2024-02-14 SC 13G KYNAM CAPITAL MANAGEMENT, LP 0001085146-24-001353 005-89449 24635177 34 44203
2024-02-14 SC 13G/A SYNDAX PHARMACEUTICALS, INC. 0000902664-24-001533 005-89449 24632188 34 102900
2024-02-13 SC 13G/A d10978793_13g-a.htm 0000919574-24-001234 005-89449 24631642 34 167406
2024-02-13 SC 13G SCHEDULE 13G 0001104659-24-022051 005-89449 24629679 34 13071
2024-02-09 4 PRIMARY DOCUMENT 0001562180-24-001223 9604
2024-02-09 4 PRIMARY DOCUMENT 0001562180-24-001222 13064
2024-02-09 4 PRIMARY DOCUMENT 0001562180-24-001221 12134
2024-02-09 4 PRIMARY DOCUMENT 0001562180-24-001220 7744
2024-02-09 4 PRIMARY DOCUMENT 0001562180-24-001219 7730
2024-02-09 4 PRIMARY DOCUMENT 0001562180-24-001218 7860
2024-02-09 4 PRIMARY DOCUMENT 0001562180-24-001217 7704
2024-02-09 4 PRIMARY DOCUMENT 0001562180-24-001216 5155
2024-02-09 4 PRIMARY DOCUMENT 0001562180-24-001215 5151
2024-02-09 4 PRIMARY DOCUMENT 0001562180-24-001214 5130
2024-02-08 SC 13G/A SEC SCHEDULE 13G 0000902219-24-000134 005-89449 24607356 34 37854
2024-01-25 SC 13G/A us87164f1057_012524.txt 0001086364-24-003711 005-89449 24562937 34 13655
2024-01-25 SC 13G/A SyndaxPharma.txt 0000093751-24-000236 005-89449 24560095 34 8560
2023-12-20 8-K 8-K 8.01,9.01 0000950170-23-071749 001-37708 231499465 34 224580 1 1
2023-12-15 8-K 8-K 1.01,9.01 0001193125-23-296814 001-37708 231491492 34 427448 1 1
2023-12-15 424B5 424B5 0001193125-23-296813 333-254661 231491488 33 773224
2023-12-14 424B5 424B5 0001193125-23-295515 333-254661 231487419 33 744442
2023-12-12 8-K 8-K 8.01,9.01 0000950170-23-069683 001-37708 231481236 34 363043 1 1
2023-12-07 UPLOAD filename1.pdf 0000000000-23-013348 39667
2023-11-28 CORRESP filename1.htm 0000950170-23-066397 299993
2023-11-13 UPLOAD filename1.pdf 0000000000-23-012422 44691
2023-11-02 10-Q 10-Q 0000950170-23-058165 001-37708 231372208 34 9724340 1 1
2023-11-02 8-K 8-K 2.02,9.01 0000950170-23-058156 001-37708 231372100 34 428610 1 1
2023-10-31 SC 13G SYNDAX PHARMACEUTICALS INC 0000902664-23-005275 005-89449 231365054 34 111624
2023-10-05 SC 13G/A SC 13G/A 0001193125-23-251311 005-89449 231310583 34 309848
2023-10-02 8-K 8-K 8.01,9.01 0000950170-23-050922 001-37708 231297695 34 240617 1 1
2023-08-10 4 PRIMARY DOCUMENT 0001562180-23-006262 8867
2023-08-09 144 xsl144X01/primary_doc.xml 0001950047-23-002895 001-37708 231155350 33 6230
2023-08-03 10-Q 10-Q 0000950170-23-037943 001-37708 231139869 34 9716402 1 1
2023-08-03 8-K 8-K 2.02,9.01 0000950170-23-037936 001-37708 231139806 34 447856 1 1
2023-08-03 4 PRIMARY DOCUMENT 0001562180-23-006130 18994
2023-08-02 144 xsl144X01/primary_doc.xml 0001959173-23-002843 001-37708 231137430 33 5465
2023-07-24 8-K 8-K 8.01,9.01 0000950170-23-033937 001-37708 231103728 34 275949 1 1
2023-07-11 4 PRIMARY DOCUMENT 0001562180-23-005845 8867
2023-07-10 144 xsl144X01/primary_doc.xml 0001950047-23-002201 001-37708 231079866 33 6231
2023-06-14 4 PRIMARY DOCUMENT 0001562180-23-005152 4907
2023-06-09 4 PRIMARY DOCUMENT 0001562180-23-005057 14065
2023-06-09 144 xsl144X01/primary_doc.xml 0001950047-23-001446 001-37708 231005428 33 6973
2023-05-26 8-K 8-K 1.02,8.01,9.01 0000950170-23-024544 001-37708 23969841 34 723331 1 1
2023-05-26 424B5 424B5 0001193125-23-155499 333-254661 23969712 33 849434
2023-05-18 8-K 8-K 3.03,5.03,5.07,9.01 0000950170-23-022802 001-37708 23933147 34 228511 1 1
2023-05-10 4 PRIMARY DOCUMENT 0001562180-23-004032 8866
2023-05-09 144 xsl144X01/primary_doc.xml 0001950047-23-000482 001-37708 23902442 33 6265
2023-05-08 10-Q 10-Q 0000950170-23-018806 001-37708 23897824 34 8125502 1 1
2023-05-08 8-K 8-K 2.02,5.02,9.01 0000950170-23-018794 001-37708 23897753 34 402310 1 1
2023-04-18 DEFA14A DEFA14A 0000950170-23-013259 001-37708 23826761 34 72522
2023-04-12 4 PRIMARY DOCUMENT 0001562180-23-003521 8866
2023-04-12 4 PRIMARY DOCUMENT 0001562180-23-003520 5688
2023-04-12 3 PRIMARY DOCUMENT 0001562180-23-003519 3118
2023-04-07 ARS ARS 0000950170-23-012192 001-37708 23808819 34 1276199
2023-04-07 DEFA14A DEFA14A 0000950170-23-012191 001-37708 23808797 34 2083617
2023-04-07 DEF 14A DEF 14A 0000950170-23-012189 001-37708 23808774 34 8899975 1 1
2023-03-30 8-K 8-K 5.02,7.01,9.01 0000950170-23-010756 001-37708 23777192 34 547093 1 1
2023-03-28 PRE 14A PRE 14A 0000950170-23-010296 001-37708 23769765 34 8911331 1 1
2023-03-14 4 PRIMARY DOCUMENT 0001562180-23-002770 9077
2023-02-28 S-8 S-8 0000950170-23-005102 333-270093 23685528 33 272008
2023-02-28 10-K 10-K 0000950170-23-005079 001-37708 23685259 34 14425835 1 1
2023-02-28 8-K 8-K 2.02,9.01 0000950170-23-005069 001-37708 23685137 34 464374 1 1
2023-02-17 4 PRIMARY DOCUMENT 0001562180-23-001533 14380
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-021838 005-89449 23630797 34 49618
2023-02-14 SC 13G/A d9942499_13g-a.htm 0000919574-23-001638 005-89449 23628213 34 164616
2023-02-14 SC 13G/A SC 13G/A 0001193125-23-038098 005-89449 23625338 34 329484
2023-02-14 SC 13G/A AMENDMENT NO. 7 TO THE SCHEDULE 13G 0000921895-23-000531 005-89449 23625060 34 277033
2023-02-08 4 PRIMARY DOCUMENT 0001562180-23-001118 8940
2023-02-08 4 PRIMARY DOCUMENT 0001562180-23-001117 8968
2023-02-08 8-K 8-K 5.02,9.01 0000950170-23-002172 001-37708 23599586 34 759365 1 1
2023-02-06 SC 13G/A Syndax_Pharmaceuticals_Inc.txt 0000093751-23-000262 005-89449 23590049 34 8491
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000956 5442
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000955 5466
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000954 5533
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000953 5407
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000950 8703
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000948 5439
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000947 5033
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000946 5028
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000945 5019
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000944 5012
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000943 5029
2023-02-03 4 PRIMARY DOCUMENT 0001562180-23-000942 5028
2023-02-01 SC 13G/A us87164f1057_013123.txt 0001306550-23-005951 005-89449 23573989 34 13371
2023-01-13 4 PRIMARY DOCUMENT 0001562180-23-000413 19215
2023-01-10 SC 13G SEC SCHEDULE 13G 0000902219-23-000002 005-89449 23519835 34 37888
2022-12-14 8-K 8-K 2.02,7.01,9.01 0000950170-22-026546 001-37708 221462514 34 222238 1 1
2022-12-07 8-K 8-K 1.01,9.01 0001193125-22-300218 001-37708 221450784 34 423112 1 1
2022-12-07 424B5 424B5 0001193125-22-300140 333-254661 221450263 33 598419
2022-12-06 424B5 424B5 0001193125-22-299481 333-254661 221448383 33 569193
2022-12-05 4 PRIMARY DOCUMENT 0001562180-22-008056 5651
2022-12-05 3 PRIMARY DOCUMENT 0001562180-22-008047 3115
2022-12-05 8-K 8-K 5.02,9.01 0000950170-22-026017 001-37708 221443734 34 536684 1 1
2022-12-02 4 PRIMARY DOCUMENT 0001562180-22-008017 19433
2022-11-03 10-Q 10-Q 0000950170-22-021848 001-37708 221357970 34 10726277 1 1
2022-11-03 8-K 8-K 2.02,9.01 0000950170-22-021838 001-37708 221357861 34 476684 1 1
2022-10-07 4 PRIMARY DOCUMENT 0001562180-22-007125 14349
2022-10-07 4 PRIMARY DOCUMENT 0001562180-22-007124 9058
2022-10-04 4 PRIMARY DOCUMENT 0001562180-22-007012 19412
2022-10-04 4 PRIMARY DOCUMENT 0001562180-22-007011 34929
2022-09-23 8-K 8-K 1.02,7.01,9.01 0000950170-22-018819 001-37708 221262370 34 183626 1 1
2022-09-21 4 PRIMARY DOCUMENT 0001562180-22-006788 14257
2022-09-16 4 PRIMARY DOCUMENT 0001562180-22-006706 24729
2022-09-16 4 PRIMARY DOCUMENT 0001562180-22-006705 19377
2022-08-26 4 PRIMARY DOCUMENT 0001562180-22-006334 15908
2022-08-09 4 PRIMARY DOCUMENT 0001562180-22-005979 14109
2022-08-08 10-Q 10-Q 0000950170-22-015523 001-37708 221144460 34 9749061 1 1
2022-08-08 8-K 8-K 2.02,9.01 0000950170-22-015507 001-37708 221144287 34 543555 1 1
2022-07-27 4 PRIMARY DOCUMENT 0001562180-22-005761 14313
2022-07-08 4 PRIMARY DOCUMENT 0001562180-22-005637 14136
2022-07-05 4 PRIMARY DOCUMENT 0001562180-22-005475 8970
2022-06-15 4 PRIMARY DOCUMENT 0001562180-22-005117 7351
2022-06-15 3 PRIMARY DOCUMENT 0001562180-22-005116 3116
2022-06-13 8-K 8-K 5.02,9.01 0001564590-22-023045 001-37708 221010705 34 437774 1 1
2022-05-11 8-K 8-K 5.07,9.01 0001564590-22-019515 001-37708 22913614 34 182851 1 1
2022-05-09 8-K 8-K 2.02,9.01 0001564590-22-018892 001-37708 22905417 34 364830 1 1
2022-05-09 10-Q 10-Q 0001564590-22-018873 001-37708 22905051 34 8234480 1 1
2022-04-13 4/A PRIMARY DOCUMENT 0001562180-22-003383 11065
2022-04-05 4 PRIMARY DOCUMENT 0001562180-22-003223 17560
2022-03-30 DEFA14A DEFA14A 0001564590-22-012595 001-37708 22786380 34 1436669
2022-03-29 DEF 14A DEF 14A 0001564590-22-012198 001-37708 22780710 34 2524631
2022-03-04 SC 13D/A SC 13D/A 0001193125-22-066275 005-89449 22715069 34 135929
2022-03-03 4 PRIMARY DOCUMENT 0001562180-22-002258 5774
2022-03-03 3 PRIMARY DOCUMENT 0001562180-22-002247 6933
2022-03-01 S-8 S-8 0001564590-22-008120 333-263185 22699927 33 169925
2022-03-01 10-K 10-K 0001564590-22-008112 001-37708 22699849 34 15942998 1 1
2022-03-01 8-K 8-K 2.02,5.02,7.01,9.01 0001564590-22-008030 001-37708 22697849 34 748341 1 1
2022-02-24 8-K 8-K 5.02,9.01 0001564590-22-006493 001-37708 22666474 34 164238 1 1
2022-02-14 SC 13G/A AMENDMENT NO. 6 TO THE SCHEDULE 13G 0000921895-22-000518 005-89449 22628672 34 283560
2022-02-14 SC 13G SC 13G 0001104659-22-021727 005-89449 22625635 34 50405
2022-02-14 SC 13G/A d9178725_13g-a.htm 0000919574-22-001210 005-89449 22624148 34 168266
2022-02-10 SC 13G/A SYNDAX PHARMACEUTICALS, INC. 0000902664-22-001387 005-89449 22611934 34 107620
2022-02-07 SC 13G/A us87164f1057_020722.txt 0000834237-22-007901 005-89449 22598083 34 13371
2022-02-04 SC 13G/A SEC SCHEDULE 13G 0001678858-22-000232 005-89449 22591435 34 33145
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001081 5759
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001080 5786
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001079 8710
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001078 7226
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001077 8677
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001076 5032
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001074 5029
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001073 5012
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001072 5029
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001071 7612
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001070 5019
2022-02-03 4 PRIMARY DOCUMENT 0001562180-22-001069 5028
2022-02-03 8-K 8-K 5.02,7.01,9.01 0001564590-22-003814 001-37708 22588224 34 713389 1 1
2022-01-03 4 PRIMARY DOCUMENT 0001562180-22-000035 7172
2021-12-23 SC 13G cmw354.htm 0000897069-21-000610 005-89449 211518207 34 163945
2021-12-23 8-K 8-K 1.01,2.03,9.01 0001564590-21-061135 001-37708 211517117 34 177279 1 1
2021-12-22 4 PRIMARY DOCUMENT 0001562180-21-007866 14195
2021-12-20 4 PRIMARY DOCUMENT 0001562180-21-007810 8843
2021-12-20 4 PRIMARY DOCUMENT 0001562180-21-007809 24689
2021-12-17 8-K 8-K 1.01,9.01 0001193125-21-361105 001-37708 211501677 34 524151 1 1
2021-12-17 424B5 424B5 0001193125-21-361097 333-254661 211501599 33 871142
2021-12-16 424B5 424B5 0001193125-21-358492 333-254661 211495943 33 859909
2021-12-15 4 PRIMARY DOCUMENT 0001562180-21-007710 14131
2021-12-13 8-K 8-K 8.01,9.01 0001564590-21-060153 001-37708 211488071 34 300443 1 1
2021-12-09 8-K 8-K 8.01,9.01 0001564590-21-059911 001-37708 211482733 34 214632 1 1
2021-12-09 424B5 424B5 0001193125-21-352755 333-254661 211482649 33 684935
2021-11-19 4 PRIMARY DOCUMENT 0001562180-21-007180 13849
2021-11-15 10-Q 10-Q 0001564590-21-057004 001-37708 211410590 34 11414627 1 1
2021-11-15 8-K 8-K 2.02,9.01 0001564590-21-056999 001-37708 211410334 34 1274199 1 1
2021-11-04 3 PRIMARY DOCUMENT 0001562180-21-006828 16062
2021-10-27 4 PRIMARY DOCUMENT 0001562180-21-006652 14167
2021-10-06 4 PRIMARY DOCUMENT 0001562180-21-006357 4890
2021-10-04 8-K 8-K 5.02,9.01 0001564590-21-050013 001-37708 211302593 34 170301 1 1
2021-09-28 4 PRIMARY DOCUMENT 0001562180-21-006136 8777
2021-09-27 8-K 8-K 1.01,7.01,9.01 0001564590-21-048947 001-37708 211278895 34 278377 1 1
2021-09-22 4 PRIMARY DOCUMENT 0001562180-21-006060 19542
2021-09-21 4 PRIMARY DOCUMENT 0001562180-21-006038 14060
2021-09-17 4 PRIMARY DOCUMENT 0001562180-21-006002 5489
2021-09-17 3 PRIMARY DOCUMENT 0001562180-21-006001 5742
2021-09-15 8-K 8-K 5.02,9.01 0001564590-21-048050 001-37708 211255891 34 351774 1 1
2021-09-15 4 PRIMARY DOCUMENT 0001562180-21-005948 14165
2021-08-20 4 PRIMARY DOCUMENT 0001562180-21-005491 8925
2021-08-09 10-Q 10-Q 0001564590-21-042657 001-37708 211156728 34 9309996 1 1
2021-08-09 S-8 S-8 0001564590-21-042630 333-258628 211156531 33 156983
2021-08-09 8-K 8-K 2.02,9.01 0001564590-21-042626 001-37708 211156510 34 703515 1 1
2021-05-20 4 PRIMARY DOCUMENT 0001562180-21-003670 13948
2021-05-13 8-K 8-K 5.07 0001564590-21-027518 001-37708 21919502 34 175538 1 1
2021-05-11 10-Q 10-Q 0001564590-21-026548 001-37708 21911423 34 7778791 1 1
2021-05-11 8-K 8-K 2.02,9.01 0001564590-21-026549 001-37708 21911399 34 575191 1 1
2021-05-10 SC 13G SYNDAX PHARMACEUTICALS INC. 0000902664-21-002667 005-89449 21907052 34 106335
2021-05-03 SC 13D SCHEDULE 13D 0001193125-21-147745 005-89449 21883177 34 201094
2021-04-30 10-K/A 10-K/A 0001564590-21-022519 001-37708 21877725 34 451206 1 1
2021-04-28 4 PRIMARY DOCUMENT 0001562180-21-002976 4687
2021-04-22 4 PRIMARY DOCUMENT 0001562180-21-002912 4790
2021-04-20 SC 13G/A d8844143_13g-a.htm 0000919574-21-003048 005-89449 21838275 34 164016
2021-04-01 DEF 14A DEF 14A 0001564590-21-017347 001-37708 21799104 34 2342349
2021-03-24 S-3ASR S-3ASR 0001193125-21-092731 333-254661 21768843 33 1481334
2021-03-24 RW RW 0001193125-21-092728 333-254574 21768821 NE 6483
2021-03-22 S-3 S-3 0001193125-21-089573 333-254574 21761569 33 1480775
2021-03-12 10-K 10-K 0001564590-21-012607 001-37708 21734614 34 12510916 1 1
2021-03-08 8-K 8-K 2.02,9.01 0001564590-21-011477 001-37708 21721906 34 462304 1 1
2021-03-03 4 PRIMARY DOCUMENT 0001562180-21-001909 14107
2021-02-16 SC 13G/A SC 13G/A 0001193125-21-044932 005-89449 21638937 34 87120
2021-02-16 SC 13G/A d8798761_13g-a.htm 0000919574-21-001342 005-89449 21634466 34 186282
2021-02-12 SC 13G/A AMENDMENT NO. 5 TO THE SCHEDULE 13G 0000921895-21-000391 005-89449 21629663 34 285248
2021-02-12 SC 13G/A SC 13G/A 0001193125-21-041467 005-89449 21627252 34 172404
2021-02-10 4 PRIMARY DOCUMENT 0001562180-21-001044 8964
2021-02-05 8-K 8-K 5.02 0001564590-21-004514 001-37708 21596001 34 178872 1 1
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000935 5434
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000934 5465
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000933 5400
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000932 7223
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000931 8981
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000930 5033
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000929 5020
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000928 5013
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000925 5030
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000927 5030
2021-02-05 4 PRIMARY DOCUMENT 0001562180-21-000926 5029
2021-02-04 SC 13G/A SEC SCHEDULE 13G 0000902219-21-000181 005-89449 21589452 34 37615
2021-02-04 SC 13G/A SC 13G/A 0001193125-21-027666 005-89449 21588317 34 114424
2021-02-03 4 PRIMARY DOCUMENT 0001562180-21-000869 8933
2021-02-02 SC 13G us87164f1057_020221.txt 0000834237-21-007058 005-89449 21580839 34 13215
2021-01-21 SC 13G/A SCHEDULE 13G/A FOR SYNDAX PHARMACEUTICALS, INC. ON BEHALF OF DOMAIN PARTNERS VII 0000904454-21-000041 005-89449 21540088 34 61766
2020-12-10 SC 13G/A SEC SCHEDULE 13G 0000902219-20-000443 005-89449 201379522 34 33368
2020-12-09 8-K 8-K 1.01,9.01 0001193125-20-313808 001-37708 201377891 34 424807 1 1
2020-12-09 424B5 424B5 0001193125-20-313801 333-233564 201377870 33 996696
2020-12-07 8-K 8-K 1.02,8.01,9.01 0001193125-20-311904 001-37708 201373566 34 279536 1 1
2020-12-07 424B5 424B5 0001193125-20-311899 333-233564 201373543 33 720846
2020-12-03 4 PRIMARY DOCUMENT 0001562180-20-007070 8816
2020-11-25 4 PRIMARY DOCUMENT 0001562180-20-006920 15367
2020-11-12 4 PRIMARY DOCUMENT 0001562180-20-006681 14002
2020-11-06 4 PRIMARY DOCUMENT 0001562180-20-006583 8546
2020-11-05 10-Q 10-Q 0001564590-20-051287 001-37708 201290352 34 10503573 1 1
2020-11-04 SC 13G d8641259_13g.htm 0000919574-20-006675 005-89449 201287485 34 201361
2020-11-02 8-K 8-K 2.02,9.01 0001564590-20-049638 001-37708 201280521 34 423983 1 1
2020-09-09 SC 13G/A us87164f1057_090920.txt 0000834237-20-010194 005-89449 201166510 34 12260
2020-08-06 10-Q 10-Q 0001564590-20-037777 001-37708 201082031 34 9463584 1 1
2020-08-06 S-8 S-8 0001564590-20-037767 333-241654 201081936 33 142980
2020-08-06 8-K 8-K 2.02,9.01 0001564590-20-037719 001-37708 201081559 34 445980 1 1
2020-07-13 3 PRIMARY DOCUMENT 0001562180-20-005102 4507
2020-07-08 4 PRIMARY DOCUMENT 0001562180-20-005074 4879
2020-07-07 8-K 8-K 5.02,9.01 0001564590-20-031882 001-37708 201015222 34 219184
2020-06-09 8-K 8-K 5.07 0001564590-20-028764 001-37708 20951814 34 35530
2020-05-11 SC 13G SC 13G 0001193125-20-139263 005-89449 20866031 34 108450
2020-05-07 10-Q 10-Q 0001564590-20-022971 001-37708 20857286 34 8097293 1
2020-05-07 8-K 8-K 2.02,9.01 0001564590-20-022849 001-37708 20856406 34 262646
2020-05-04 8-K 8-K 1.01,8.01,9.01 0001564590-20-020633 001-37708 20842919 34 457729
2020-05-04 424B5 424B5 0001564590-20-020574 333-233564 20842274 33 1243631
2020-04-30 8-K 8-K 2.02,8.01,9.01 0001564590-20-019941 001-37708 20833056 34 555524
2020-04-30 424B5 424B5 0001564590-20-019928 333-233564 20833014 33 1283549
2020-04-29 DEF 14A DEF 14A 0001564590-20-019694 001-37708 20830166 34 1248442
2020-03-05 10-K 10-K 0001564590-20-009016 001-37708 20691835 34 9979233 1
2020-03-03 8-K 8-K 2.02,9.01 0001564590-20-008426 001-37708 20682063 34 279141
2020-02-20 8-K 8-K 5.02 0001564590-20-005551 001-37708 20635030 34 48765
2020-02-14 SC 13G/A AMENDMENT NO. 4 TO THE SCHEDULE 13G 0000921895-20-000574 005-89449 20621956 34 307900
2020-02-14 4 PRIMARY DOCUMENT 0001562180-20-001238 7092
2020-02-14 4 PRIMARY DOCUMENT 0001562180-20-001237 8957
2020-02-14 4 PRIMARY DOCUMENT 0001562180-20-001236 5468
2020-02-14 4 PRIMARY DOCUMENT 0001562180-20-001235 5463
2020-02-14 4 PRIMARY DOCUMENT 0001562180-20-001234 5464
2020-02-14 4 PRIMARY DOCUMENT 0001562180-20-001233 5305
2020-02-14 4 PRIMARY DOCUMENT 0001562180-20-001232 5304

Latest XBRL company facts

One latest value per concept from companyfacts (325 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 89.30M 2026-07-31 2026 Q2 10-Q 2026-08-04 0001193125-26-332750
dei EntityPublicFloat Entity Public Float USD 799.20M 2025-06-30 2025 FY 10-K 2026-02-26 0001193125-26-076536
ecd CoSelectedMeasureAmt CoSelectedMeasureAmt USDPerShare 21.01 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197859
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 3.61M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197859
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 2.45M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197859
ecd PeerGroupTotalShareholderRtnAmt PeerGroupTotalShareholderRtnAmt USD 124.75 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197859
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 94.47 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197859
us-gaap AccountsAndOtherReceivablesNetCurrent Accounts and Other Receivables, Net, Current USD 46.87M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 3.57M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 38.00M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 3.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 116.86M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 37.69M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 440,000 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD -1.67M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 484.89M 2018-09-30 2018 Q3 10-Q 2018-11-05 0001564590-18-026892
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.63B 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AdjustmentOfWarrantsGrantedForServices Adjustment of Warrants Granted for Services USD -1,000 2023-04-01 2023-06-30 2023 Q3 10-Q 2023-11-02 0000950170-23-058165
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 15.48M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 7.19M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap AdjustmentsToAdditionalPaidInCapitalStockSplit Adjustments to Additional Paid in Capital, Stock Split USD 1,000 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 16.78M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012607
us-gaap AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net USD 92,000 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0001564590-22-018873
us-gaap AdvertisingExpense Advertising Expense USD 14.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 41.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap AmortizationOfFinancingCosts Amortization of Debt Issuance Costs USD 538,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AmortizationOfFinancingCostsAndDiscounts Amortization of Debt Issuance Costs and Discounts USD 762,000 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap Assets Assets USD 692.67M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AssetsCurrent Assets, Current USD 567.44M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 1.67M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 416.81M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 415.14M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap AvailableForSaleSecuritiesGrossRealizedGainLossNet Available-for-sale Securities, Gross Realized Gain (Loss) USD 0 2018-01-01 2018-06-30 2018 Q2 10-Q 2018-08-08 0001564590-18-020483
us-gaap BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability USD 0 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 42,000 2017-01-01 2017-09-30 2018 Q3 10-Q 2018-11-05 0001564590-18-026892
us-gaap CapitalLeasesFutureMinimumPaymentsDue Capital Leases, Future Minimum Payments Due USD 13,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap CapitalLeasesFutureMinimumPaymentsDueCurrent Capital Leases, Future Minimum Payments Due, Next Twelve Months USD 4,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap CapitalLeasesFutureMinimumPaymentsDueInFiveYears Capital Leases, Future Minimum Payments Due in Five Years USD 0 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap CapitalLeasesFutureMinimumPaymentsDueInFourYears Capital Leases, Future Minimum Payments Due in Four Years USD 1,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap CapitalLeasesFutureMinimumPaymentsDueInThreeYears Capital Leases, Future Minimum Payments Due in Three Years USD 4,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap CapitalLeasesFutureMinimumPaymentsDueInTwoYears Capital Leases, Future Minimum Payments Due in Two Years USD 4,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap CapitalLeasesFutureMinimumPaymentsDueThereafter Capital Leases, Future Minimum Payments Due Thereafter USD 0 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments Capital Leases, Future Minimum Payments, Interest Included in Payments USD 2,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments USD 11,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 135.94M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 11.32M 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 113.20M 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012378
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 28.20M 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012378
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 136.04M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 1.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 0 2019-03-31 2019 Q3 10-Q 2019-11-07 0001564590-19-041719
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 30.34M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 200.00M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 89.99M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 89.99M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap CommonStockValue Common Stock, Value, Issued USD 9,000 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -285.13M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 1.52M 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008112
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 11.62M 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008112
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 328.94M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap ConvertibleLongTermNotesPayable Convertible Notes Payable, Noncurrent USD 244.19M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 5.21M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap DebtCurrent Debt, Current USD 344.10M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 20.00M 2022-06-30 2022 Q2 10-Q 2022-08-08 0000950170-22-015523
us-gaap DebtInstrumentFaceAmount Debt Instrument, Face Amount USD 5.00M 2014-09-30 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction USD 250,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-sale, Realized Gain (Loss) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap DecreaseInRestrictedCash Decrease in Restricted Cash USD 2,000 2016-01-01 2016-03-31 2016 Q1 10-Q 2016-05-16 0001193125-16-591861
us-gaap DeferredFinanceCostsNet Debt Issuance Costs, Net USD 5.91M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 0 2017-09-30 2017 Q3 10-Q 2017-11-08 0001193125-17-336444
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 1.52M 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012378
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 15.79M 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012378
us-gaap DeferredTaxAssetInterestCarryforward Deferred Tax Asset, Interest Carryforward USD 2.49M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 2.99M 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008112
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 339.71M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 13.52M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 79.60M 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 135.52M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsDomestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic USD 585.30M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Deferred Tax Assets, Operating Loss Carryforwards, State and Local USD 227.70M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 1.26M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsOther Deferred Tax Assets, Tax Credit Carryforwards, Other USD 26.99M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsTaxDeferredExpense Deferred Tax Assets, Tax Deferred Expense USD 53.70M 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 15.35M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 5.02M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 339.71M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 3.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap DepositLiabilitiesAccruedInterest Deposit Liabilities, Accrued Interest USD 4.93M 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030394
us-gaap DepositsAssetsCurrent Deposits Assets, Current USD 10.15M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap Depreciation Depreciation USD 15.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap DepreciationAmortizationAndAccretionNet Depreciation, Amortization and Accretion, Net USD -580,000 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-07 0001564590-19-041719
us-gaap DerivativeGainLossOnDerivativeNet Derivative, Gain (Loss) on Derivative, Net USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030394
us-gaap DerivativeLiabilitiesCurrent Derivative Liability, Current USD 0 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005079
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.59 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.63 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0001564590-22-018873
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.59 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.273 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.011 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.011 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.011 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent pure -0.095 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.009 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 14.16M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 1.70M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap FairValueAssumptionsExpectedDividendRate Fair Value Assumptions, Expected Dividend Rate (Deprecated 2018-01-31) pure 0 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap FairValueAssumptionsExpectedVolatilityRate Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) pure 0.739 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap FairValueAssumptionsRiskFreeInterestRate Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) pure 0.02 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value USD 187,000 2021-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005079
us-gaap FinanceLeaseLiabilityPaymentsDue Finance Lease, Liability, Payment, Due USD 2.24M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 122.84M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 150 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 77.52M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -59.83M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncomeTaxReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount USD 3.23M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 202,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 3.06M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 363,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 342,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncomeTaxReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount USD 26.99M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 2.53M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -13.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 8.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets Increase (Decrease) in Accounts Receivable and Other Operating Assets USD -5.71M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD 11.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -379,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012378
us-gaap IncreaseDecreaseInInventories Increase (Decrease) in Inventories USD 6.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap IncreaseDecreaseInOtherCurrentAssets Increase (Decrease) in Other Current Assets USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD -463,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030394
us-gaap IncreaseDecreaseInOtherReceivables Increase (Decrease) in Other Receivables USD 13.10M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-08 0000950170-22-015523
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -8.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap IncreaseDecreaseInRestrictedCash Increase (Decrease) in Restricted Cash USD -45,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 1.56M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap InterestExpense Interest Expense USD 100,000 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-01 0000950170-24-089241
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 4,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 1.57M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-05 0001564590-20-009016
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 2,000 2016-01-01 2016-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030394
us-gaap InterestPayableCurrent Interest Payable, Current USD 1.72M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap InterestReceivableCurrent Interest Receivable, Current USD 3.07M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap InventoryFinishedGoods Inventory, Finished Goods, Gross USD 1.17M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap InventoryGross Inventory, Gross USD 32.75M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap InventoryNet Inventory, Net USD 39.38M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap InventoryRawMaterials Inventory, Raw Materials, Gross USD 34.87M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap InventoryValuationReserves Inventory Valuation Reserves USD 200,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap InventoryWorkInProcess Inventory, Work in Process, Gross USD 3.34M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 12.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 1.74M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 656,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 59,000 2019-12-31 2019 FY 10-K 2020-03-05 0001564590-20-009016
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 403,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 676,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 142,000 2019-09-30 2019 Q3 10-Q 2019-11-07 0001564590-19-041719
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 214,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap Liabilities Liabilities USD 709.85M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 692.67M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap LiabilitiesCurrent Liabilities, Current USD 120.96M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap LiabilitiesNoncurrent Liabilities, Noncurrent USD 588.89M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap LicensesRevenue Licenses Revenue (Deprecated 2018-01-31) USD 379,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012378
us-gaap LoansPayable Loans Payable USD 20.21M 2022-06-30 2022 Q2 10-Q 2022-08-08 0000950170-22-015523
us-gaap LoansPayableCurrent Loans Payable, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap LoansPayableToBankCurrent Loans Payable to Bank, Current USD 0 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 350.00M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 14.77M 2022-06-30 2022 Q2 10-Q 2022-08-08 0000950170-22-015523
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 7.13M 2020-06-30 2020 Q2 10-Q 2020-08-06 0001564590-20-037777
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 5.24M 2021-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008112
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 5.24M 2022-06-30 2022 Q2 10-Q 2022-08-08 0000950170-22-015523
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Long-Term Debt, Maturity, Remainder of Fiscal Year USD 0 2022-06-30 2022 Q2 10-Q 2022-08-08 0000950170-22-015523
us-gaap LongTermInvestments Long-term Investments USD 123.97M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap LongTermLoansPayable Loans Payable, Noncurrent USD 0 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005079
us-gaap LongTermNotesPayable Notes Payable, Noncurrent USD 331.56M 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030394
us-gaap LossContingencyLossInPeriod Loss Contingency, Loss in Period USD 0 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-04-30 0001193125-26-197154
us-gaap MarketableSecuritiesUnrealizedGainLoss Marketable Securities, Unrealized Gain (Loss) USD -28,000 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-08 0001193125-17-336444
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 263.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 33,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012378
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -155.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD 12.64M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012378
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -107.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -19.87M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012378
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -141.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -141.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -141.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -25.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OperatingExpenses Operating Expenses USD 337.04M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -116.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 900,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 1.52M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 526,000 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 1.58M 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030394
us-gaap OperatingLeasePayments Operating Lease, Payments USD 800,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 952,000 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 1.61M 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 569,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 0 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 59,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 395,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 588,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 0 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 800,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.14 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 1.96M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OtherAssetsCurrent Other Assets, Current USD 3.51M 2024-09-30 2024 Q3 10-Q 2024-11-05 0000950170-24-121439
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 0 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030394
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -143.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -2.12M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 1,000 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008112
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap OtherNonoperatingExpense Other Nonoperating Expense USD 807,000 2025-01-01 2025-06-30 2025 Q2 10-Q 2025-08-04 0000950170-25-101985
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -777,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OtherPrepaidExpenseCurrent Other Prepaid Expense, Current USD 2.95M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OtherReceivables Other Receivables USD 697,000 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap OtherReceivablesGrossCurrent Other Receivables, Gross, Current USD 2.70M 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332750
us-gaap OtherReceivablesNetCurrent Other Receivables, Net, Current USD 3.70M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap PaidInKindInterest Paid-in-Kind Interest USD 0 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-02 0000950170-23-058165
us-gaap PaymentOfFinancingAndStockIssuanceCosts Payment of Financing and Stock Issuance Costs USD 302,000 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-14 0001193125-16-767345
us-gaap PaymentsForProceedsFromDepositOnLoan Payments for (Proceeds from) Deposit on Loan USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030394
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 6.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap PaymentsToAcquireAssetsInvestingActivities Payments to Acquire Assets, Investing Activities USD 40,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 187,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap PaymentsToAcquireShortTermInvestments Payments to Acquire Short-term Investments USD 363.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-03-31 2026 Q1 10-Q 2026-04-30 0001193125-26-197154
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-03-31 2026 Q1 10-Q 2026-04-30 0001193125-26-197154
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-03-31 2026 Q1 10-Q 2026-04-30 0001193125-26-197154
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-03-31 2026 Q1 10-Q 2026-04-30 0001193125-26-197154
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 14.09M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap PrepaidInsurance Prepaid Insurance USD 1.57M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap PrepaidRent Prepaid Rent USD 56,000 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap ProceedsFromConvertibleDebt Proceeds from Convertible Debt USD 250.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap ProceedsFromDebtNetOfIssuanceCosts Proceeds from Debt, Net of Issuance Costs USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005079
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 52.15M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 81.20M 2021-12-01 2021-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 87.32M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt USD 14.00M 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-14 0001193125-17-081863
us-gaap ProceedsFromLicenseFeesReceived Proceeds from License Fees Received USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap ProceedsFromPaymentsForOtherFinancingActivities Proceeds from (Payments for) Other Financing Activities USD 0 2021-01-01 2021-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005079
us-gaap ProceedsFromRepaymentsOfDebt Proceeds from (Repayments of) Debt USD -750,000 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-14 0001193125-16-767345
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 208.93M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap ProceedsFromSaleOfMachineryAndEquipment Proceeds from Sale of Machinery and Equipment USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030394
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 19.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 625,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -141.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 646,000 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 206,000 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap ProvisionForOtherCreditLosses Provision for Other Credit Losses USD 3.67M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap RepaymentsOfLongTermCapitalLeaseObligations Repayments of Long-term Capital Lease Obligations USD 1,000 2016-01-01 2016-03-31 2016 Q1 10-Q 2016-05-16 0001193125-16-591861
us-gaap RepaymentsOfLongTermDebt Repayments of Long-term Debt USD 9.00M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 194.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap RestrictedCash Restricted Cash USD 0 2022-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005079
us-gaap RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents USD 216,000 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 115,000 2020-09-30 2020 Q3 10-Q 2020-11-05 0001564590-20-051287
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 102,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 102,000 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.65B 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 220.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap RoyaltyExpense Royalty Expense USD 35.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap SalesRevenueNet Revenue, Net (Deprecated 2018-01-31) USD 379,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-09 0001564590-18-012378
us-gaap SellingGeneralAndAdministrativeExpense Selling, General and Administrative Expense USD 179.68M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 41.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.68 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.041 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 30.17M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 7.53M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 14.32 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 6.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 1.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 19.62 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 7,778 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-03 0000950170-22-021848
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 3.98M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 8.74 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 56.88M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 13.13M 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 17.74 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 55.09M 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 10.68M 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 17.78 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 10.67 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 9.85 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-05 0001564590-20-009016
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 13.64 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap SharesIssued Shares, Issued shares 84.81M 2023-12-19 8-K 2023-12-20 0000950170-23-071749
us-gaap SharesIssuedPricePerShare Shares Issued, Price Per Share USD/shares 8 2020-01-31 2022 Q3 10-Q 2022-11-03 0000950170-22-021848
us-gaap SharesOutstanding Shares, Outstanding shares 84.81M 2023-12-19 8-K 2023-12-20 0000950170-23-071749
us-gaap ShortTermInvestments Short-term Investments USD 291.16M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD -17.18M 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.8 2016-02-24 2016 FY 10-K 2017-03-14 0001193125-17-081863
us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Stock Issued During Period, Shares, Employee Stock Purchase Plans shares 0 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-08 0001193125-17-336444
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 12.43M 2023-12-01 2023-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 1.14M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 321.71M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 39,000 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-08 0001193125-17-336444
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 24.85M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 59,000 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-05 0001564590-20-009016
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 3.20M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap StockRepurchasedAndRetiredDuringPeriodValue Stock Repurchased and Retired During Period, Value USD 16.78M 2018-01-01 2018-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012607
us-gaap StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares shares 16,731 2016-01-01 2016-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap Supplies Prepaid Supplies USD 58,000 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008112
us-gaap TangibleAssetImpairmentCharges Tangible Asset Impairment Charges USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap TemporaryEquityAccretionToRedemptionValueAdjustment Temporary Equity, Accretion to Redemption Value, Adjustment USD 69.72M 2015-01-01 2015-12-31 2017 FY 10-K 2018-03-08 0001564590-18-004911
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 319.11M 2015-12-31 2016 FY 10-K 2017-03-14 0001193125-17-081863
us-gaap TemporaryEquityDividendsAdjustment Temporary Equity, Dividends, Adjustment USD 2.60M 2016-01-01 2016-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap UnamortizedDebtIssuanceExpense Unamortized Debt Issuance Expense USD 87,000 2022-06-30 2022 Q2 10-Q 2022-08-08 0000950170-22-015523
us-gaap UnamortizedLossReacquiredDebtNoncurrent Unamortized Loss Reacquired Debt, Noncurrent USD 49,000 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022971
us-gaap UndistributedEarningsOfForeignSubsidiaries Undistributed Earnings of Foreign Subsidiaries USD 0 2018-12-31 2018 FY 10-K 2019-03-07 0001564590-19-006772
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 143,000 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap UnrecognizedTaxBenefitsPeriodIncreaseDecrease Unrecognized Tax Benefits, Period Increase (Decrease) USD 100,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021253
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 81.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-26 0001193125-26-076536
us-gaap WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount USD 3.91M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-01 0001564590-22-008112
us-gaap WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 USD 3.91M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0000950170-23-005079
us-gaap WarrantsAndRightsOutstanding Warrants and Rights Outstanding USD 2.85M 2015-12-31 2016 FY 10-K 2017-03-14 0001193125-17-081863
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 89.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 58.98M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0001564590-22-018873
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 89.02M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-02 0001193125-26-443625

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →